Graft Versus Host Disease (GvHD) Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) - Estimates DelveInsight | Incyte (axatilimab), Amgen, AstraZeneca, Biogen, CSL, Takeda, GlaxoSmithKline, MaaT Pharma, Roche, Syndax

The Graft Versus Host Disease (GvHD) market is dynamically evolving with advancements in targeted therapies and improved understanding of immune modulation, offering new hope for patients grappling with this complex condition. Emerging treatments and personalized approaches signify promising prospects for more effective management and enhanced patient outcomes in the future.

DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graft Versus Host Disease Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Graft Versus Host Disease therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Graft Versus Host Disease treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Graft Versus Host Disease (GvHD): An Overview
Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host's tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).

The two main types of GvHD are acute GvHD and chronic GvHD. Other than this, GvHD is classified into other types, namely: classic acute GvHD, persistent, recurrent, late-onset acute GvHD, classic chronic GvHD, overlap syndrome, and de novo chronic GvHD. Patients who get acute GvHD have a 50% chance of developing chronic GvHD.

Acute GvHD (aGvHD) might occur once the donor's cells have engrafted in the transplant recipient and have been observed to affect the skin, liver, or gastrointestinal tract. Symptoms might appear within 3 months after the transplant.

Graft Versus Host Disease (GvHD) Market Key Facts
• In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting an increase in cases by 2032.
• The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.
• GvHD is categorized into two types: aGvHD and cGvHD. In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2032. Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.
• In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight's analysis, around 3,278 cases of cGvHD were treated in the first line in the United States in 2020.
• The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.
• Major pharma giants such as CSL Behring [CSL 964 Alpha-1 antitrypsin (AAT)], Medac [obnitix (MC0518)], Equillium/Biocon [itolizumab], OncoImmune/Merck (MSD) [MK-7110 (CD24Fc)], ElsaLys Biotech/Mediolanum Farmaceutici Spa [Leukotac (inolimomab)], Xenikos [T-Guard], Mesoblast/Osiris Therapeutics [RYONCIL (remestemcel-L; prochymal)], Syndax Pharmaceutical [axatilimab (SNDX-6532)], Regimmune Corporation (RGI-2001) and several others are actively involved in the development of novel therapies.

Get a Detailed Overview of the Evolving Graft Versus Host Disease Market Trends @
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Graft Versus Host Disease (GvHD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Graft Versus Host Disease therapies in the market. It also provides a detailed assessment of the Graft Versus Host Disease market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Graft Versus Host Disease drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Graft Versus Host Disease Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Graft Versus Host Disease (GvHD) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Graft Versus Host Disease patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Graft Versus Host Disease Epidemiology Segmented as -
• Total Hematopoietic stem-cell transplantation (HSCT)
• Total Allogeneic Transplant cases, Total GvHD cases by Types (Acute and Chronic)
• Total Incident Cases of aGvHD by Grading and Organ Involvement
• Total Incident cases of cGvHD by Grading and organ involvement
• Total Treated patients of GvHD and Mortality adjusted GvHD treated patients

Get Key Insights Into the Evolving Graft Versus Host Disease Epidemiology Trends @
https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Graft Versus Host Disease (GvHD) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft Versus Host Disease market or expected to be launched during the study period. The analysis covers the market share by Graft Versus Host Disease drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Graft Versus Host Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Graft Versus Host Disease Market @
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Graft Versus Host Disease (GvHD) Therapeutics Assessment
Treatment is grounded on drugs that reduce the body's immune response and reduce T cells' number. The current hallmark of treatment for GvHD is Immunosuppressant medications. These include both corticosteroid drugs and more advanced medications and techniques that decrease the immune response.

Commonly used medications that are given in the management of GvHD include steroids (prednisolone; Methylprednisolone), Calcineurin inhibitors (Cyclosporine; Tacrolimus), Cyclophosphamide (Cytoxan), Antithymocyte globulins (Thymoglobuline; ATG-Grafalon), Monoclonal antibodies (Alemtuzumab; Infliximab; Rituximab; Basiliximab), Mechanistic target of Rapamycin (mTOR) inhibitor (Sirolimus; Everolimus), Tyrosine kinase inhibitors (Imatinib), Tumor necrosis factor (Etanercept), Thalidomide, Inosine monophosphate dehydrogenase (IMDH) inhibitor (mycophenolate mofetil), chemotherapy drugs (Pentostatin; Methotrexate), Janus kinase (JAK) inhibitor (Ruxolitinib; Itacitinib), Rho-associated coiled-coil kinase 2 (ROCK-2) inhibitor (belumosudil) and Bruton's tyrosine kinase (BTK) inhibitor (Ibrutinib).

Looking at the rising need for approved and legalized treatment options, many key companies across the world are developing novel therapies that would help in combating the complications caused by GvHD, in addition to this, the developers are also trying to come up with salvage therapy or curative therapy. Currently, ElsaLys Biotech is leading the therapeutics segment, with its drug candidates in the most advanced stage of clinical development.

On February 27, 2024, Incyte announced that the US FDA had accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024.

Leading Companies in the Graft Versus Host Disease (GvHD) Therapeutics Market Include
Some of the key companies in the Graft Versus Host Disease (GvHD) Market include AltruBio, Amgen, ASC Therapeutics, AstraZeneca, Biogen, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group, CSL Behring, CTI BioPharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Equillium, GlaxoSmithKline, Glia, Incyte Corporation, Jazz Pharmaceuticals, JCR therapeutics, Kadmon Corporation, MaaT Pharma, Medac, Medsenic, Mesoblas, Millennium Pharmaceuticals/Takeda Oncology, Novartis, OncoImmune/Merck (MSD), Osiris Therapeutics, Pfizer, Plexxikon, Prevention Bio, REGiMMUNE, Regimmune Corporation, Roche-Genentech, SCM Lifescience, Syndax Pharmaceuticals, Synthetic Biologics, Takeda, VectivBio, Xenikos, Xenothera, and others.

Emerging and Marketed Graft Versus Host Disease (GvHD) Therapies Covered in the Report Include
• AbGn-168H (Neihulizumab): AltruBio
• Arscimed (arsenic trioxide): Medsenic
• ASC930: ASC Therapeutics
• Calquence (Acalabrutinib): AstraZeneca
• CSL 964 Alpha-1 antitrypsin (AAT): CSL Behring
• Efavaleukin Alfa (AMG 592): Amgen
• EQ001 (Itolizumab; Bmab600): Equillium/Biocon
• Itacitinib: Incyte Corporation
• Jakafi (Ruxolitinib): Incyte Corporation
• KD025 (Belumosudil): Kadmon Corporation
• Leukotac (Inolimomab): ElsaLys Biotech (Mediolanum Farmaceutici Spa)
• MaaT013: MaaT Pharma
• MK-7110 (CD24Fc): OncoImmune/Merck (MSD)
• Obnitix (MC0518): Medac
• Pacritinib (Epjevy; ONX-0803): CTI BioPharma
• RGI-2001: Regimmune Corporation
• SNDX-6532 (Axatilimab; GvHD B6352): Syndax Pharmaceutical
• T-Guard: Xenikos
• Temcell (Ryoncil; Remestemcel-L; Prochymal): JCR therapeutics/ Mesoblast/ Osiris Therapeutics
• Teplizumab: Prevention Bio
• Imbruvica (Ibrutinib): Pharmacyclics (Acquired by Abbvie)/ Janssen
• Jakafi (Ruxolitinib): Incyte Corporation
• Ornecia (abatacept): Bristol Mayers Squibb
• Rezurock (Belumosudil): Kadmon Corporation (Subsidiary of Sanofi)
And Many More

Learn More About the Emerging Therapies and key Companies in the Graft Versus Host Disease Therapeutics Market @
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Graft Versus Host Disease Competitive Intelligence Analysis
4. Graft Versus Host Disease Market Overview at a Glance
5. Graft Versus Host Disease Background and Overview
6. Graft Versus Host Disease Patient Journey
7. Graft Versus Host Disease Epidemiology and Patient Population
8. Graft Versus Host Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Graft Versus Host Disease Unmet Needs
10. Key Endpoints of Graft Versus Host Disease Treatment
11. Graft Versus Host Disease Marketed Products
12. Graft Versus Host Disease Emerging Therapies
13. Graft Versus Host Disease Seven Major Market Analysis
14. Attribute Analysis
15. Graft Versus Host Disease Market Outlook (7 major markets)
16. Graft Versus Host Disease Access and Reimbursement Overview
17. KOL Views on the Graft Versus Host Disease Market.
18. Graft Versus Host Disease Market Drivers
19. Graft Versus Host Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.